Department of Pathology and Key Laboratory of Xinjiang Endemic and Ethnic Diseases, Ministry of Education, Shihezi University School of Medicine, Shihezi, Xinjiang, China.
Department of Pathology, The First Affiliated Hospital to Shihezi University School of Medicine, Shihezi, Xinjiang, China.
Biomed Res Int. 2017;2017:6705363. doi: 10.1155/2017/6705363. Epub 2017 Sep 12.
Atherosclerosis is a common inflammatory disease. Stem cell and endothelial progenitor cell treatments can improve cardiac function after myocardial infarction. Granulocyte colony-stimulating factor (G-CSF) is a mobilisation agent, mobilising stem cells from the bone marrow to circulation in the blood. G-CSF may constitute a treatment of atherosclerosis. We have conducted meta-analysis to evaluate the current evidence for the effect of G-CSF on the progression of atherosclerosis in animal models and to provide reference for preclinical experiments and future human clinical trials of atherosclerosis treatment.
We searched several databases and conducted a meta-analysis across seven articles using a random-effect model. All statistical analyses were performed using Review Manager Version 5.2 and Stata 12.0.
We found that G-CSF therapy was associated with reduced atherosclerotic lesion area (weighted mean difference (WMD): 7.29%; 95% confidence interval (CI): 2.06-12.52%; = 0.006). No significant differences in total serum cholesterol ( = 0.54) and triglyceride levels ( = 0.95) were noted in G-CSF treatment groups compared with controls. Multivariable metaregression analysis revealed that the animal type (rabbit, = 0.022) and frequency of G-CSF administration (>20, = 0.007) impacted the atherosclerotic lesion area changes.
The meta-analysis suggested that G-CSF treatment might inhibit the progression of atherosclerosis in animal models.
动脉粥样硬化是一种常见的炎症性疾病。干细胞和内皮祖细胞治疗可以改善心肌梗死后的心脏功能。粒细胞集落刺激因子(G-CSF)是一种动员剂,可将干细胞从骨髓动员到血液循环中。G-CSF 可能构成动脉粥样硬化的一种治疗方法。我们进行了荟萃分析,以评估 G-CSF 对动物模型中动脉粥样硬化进展的当前证据,并为动脉粥样硬化治疗的临床前实验和未来的人类临床试验提供参考。
我们搜索了几个数据库,并使用随机效应模型对七篇文章进行了荟萃分析。所有统计分析均使用 Review Manager Version 5.2 和 Stata 12.0 进行。
我们发现 G-CSF 治疗与减少动脉粥样硬化病变面积相关(加权均数差(WMD):7.29%;95%置信区间(CI):2.06-12.52%; = 0.006)。与对照组相比,G-CSF 治疗组的总血清胆固醇( = 0.54)和甘油三酯水平( = 0.95)无显著差异。多变量荟萃回归分析显示,动物类型(兔子, = 0.022)和 G-CSF 给药频率(>20, = 0.007)影响动脉粥样硬化病变面积的变化。
荟萃分析表明,G-CSF 治疗可能抑制动物模型中的动脉粥样硬化进展。